← Back to Clinical Trials
Recruiting NCT03649503

NCT03649503 The National Registry Study For the Real-world Patients With Parkinsonian Disorders in China

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03649503
Status Recruiting
Phase
Sponsor Huashan Hospital
Condition Parkinsonian Disorders
Study Type OBSERVATIONAL
Enrollment 100,000 participants
Start Date 2018-10-01
Primary Completion 2028-09-30

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
No intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100,000 participants in total. It began in 2018-10-01 with a primary completion date of 2028-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The overall goal of this project is to identify, assess and longitudinally monitor subjects who are interested in participating in this study. Participants will enroll through a platform named PaWei, and provide informed consent prior to any study activities. PaWei will collect a variety of information, including participants' demographic information, overall health, family history of Parkinson's Disease, other clinical information (clinical drug use, drug efficacy, and comorbid disorders), mood status, sleep, diet, exercise, memory complaints, online cognitive tests, the Short-Form 8-Item Parkinson's Disease Questionnaire (PDQ-8), Movement Disorder Society-Unified Parkinson's Disease Rating Scale IB \& II (MDS-UPDRS IB \& II), Non-Motor Symptom Aassessment Scale for Parkinson's Disease (NMSS) , Hoehn and Yahr Scale, and other scales related to quality of life, etal---all through self-reported online questionnaires. Participants will also be asked to return to the PaWei every 3 months at regular intervals, to complete follow-up scales related to quality of life, and neuropsychological assessments, etal. Anyone with Parkinsonian Disorders is welcome to participate.

Eligibility Criteria

Inclusion Criteria: Anyone with Parkinsonian Disorders is welcome to join the Registry. Exclusion Criteria:

Contact & Investigator

Central Contact

Jian Wang, MD

✉ wangjian336@hotmail.com

📞 86-21-52888160

Frequently Asked Questions

Who can join the NCT03649503 clinical trial?

This trial is open to participants of all sexes, studying Parkinsonian Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03649503 currently recruiting?

Yes, NCT03649503 is actively recruiting participants. Contact the research team at wangjian336@hotmail.com for enrollment information.

Where is the NCT03649503 trial being conducted?

This trial is being conducted at Shanghai, China, Shanghai, China.

Who is sponsoring the NCT03649503 clinical trial?

NCT03649503 is sponsored by Huashan Hospital. The trial plans to enroll 100,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology